30 results about "Colon rectum" patented technology

A device is described for measuring electrical characteristics of biological tissues with plurality of electrodes and a processor controlling the stimulation and measurement in order to detect the presence of abnormal tissue masses in organs. Examples of suitable organs are the breast, skin, oral cavity, lung, liver, colon, rectum, cervix, and prostate and determine probability of tumors containing malignant cancer cells being present in tissue. The approach can also be applied to biopsied tissue samples. The device has the capability of providing the location of the abnormality. The method for measuring electrical characteristics includes placing electrodes and applying a voltage waveform in conjunction with a current detector. A mathematical analysis method is then applied to the collected data, which computes spectrum of frequencies and correlates magnitudes and phases with given algebraic conditions to determine mass presence and type.

The present application provides novel human genes WDRPUH and KRZFPUH, and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.

The present application provides novel methods of treating and preventing colorectal cancer in a subject by administering a composition comprising beta-galactosidase, a bacterial culture (e.g., a Streptococcus thermophilus culture) capable of producing beta-galactosidase, or a culture component comprising beta-galactosidase. The invention further provides a set product for the method. In addition,the present application provides a composition for treating or preventing colon cancer.

The present invention relates to methods of detecting and / or screening for colorectal cancer (CRC), a colorectal adenoma or a polyp in a patient comprising identifying patients found to be positive for fecal occult blood and further testing for one or more additional factors. Said methods can be used to assess the suitability of a patient for colonoscopy.

The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or / and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.

Objective methods for detecting and diagnosing Colorectal and gastric carcinomas are described herein. In one embodiment, the diagnostic method involves the determining a expression level of colon or gastric cancer-associated gene that discriminate between colon or gastric cancer and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of colonic cancer and method of vaccinating a subject against colon or gastric cancer.

The invention belongs to the application field of microbial metabolites, and focuses on the application of Talaroconvolutin A in the preparation of drugs for treating colon, rectal cancer or lung cancer. Talaroconvolutin A kills cancer cells at a concentration of 0.5-50 μg / mL in vitro, and the lowest concentration that effectively kills cancer cells in 48 hours is 2 μg / mL; the effective concentration for inhibiting colon cancer cell colony formation is 2 μg / mL. IC 50 It is less than 1 μg / mL, and the effective concentration at the animal level is 5-20 mg / kg. The beneficial effects of the present invention are: IC 50 Low, minimal IC of Talaroconvolutin A at the cellular level 50 Less than 1μg / mL, the effective concentration in animals can be as low as 5mg / kg, which is obviously better than cisplatin chemotherapy drugs, and has less toxic and side effects to animals.

The invention discloses a Chinese medical rectal administration capsule for treating colonitis. Chinese medicinal powder is filled into a large-sized capsule shell. The Chinese medicinal powder is prepared from the following Chinese medical raw materials in parts by weight: 290-310 parts of underleaf pearl, 290-310 parts of geranium wilfordii, 290-310 parts of euphorbia humifusa willd, 190-210 parts of Chinese asystasiella herb, 290-310 parts of folium callicarpae pedunculatae, 140-160 parts of herba ajugae, 290-310 parts of herba agrimoniae, 390-410 parts of acalypha australis and 55-65 parts of frankincense. After the Chinese medicinal rectal administration capsule is put into anus, the capsule shell is dissolved, so that medicaments directly act on colon rectum, the effects of clearing away heat and toxic materials, scattering stasis, stopping bleeding, diminishing inflammation, sterilizing, softening hard lumps, dispelling nodes, stopping diarrhea, red white dysentery, hematuria, hematochezia, astringing dampness and relieving itching can be achieved, and chronic colonitis is cured quickly.